Five Reasons to Rethink Paper ECGs

International Pharmaceutical Industry

Inaccurate cardiac safety data can put your patients ― and trial — at unnecessary risk, so accurately identifying potential problems is crucial to keeping trials on track.

This article reviews how onsite-managed ECGs may be risking data quality, extending study timelines and increasing cost and risk. It also presents how centralized ECG data collection overcomes these challenges and enables sponsors to better protect compounds and patients.

Click here to read the full article.

Share